Top Markets
#1 Black Phoenix Black Phoenix +21,537.33%
#2 Nesa Nesa +772.80%
#3 Cortex Cortex +68.63%
#4 Kinesis Silver Kinesis Silver +55.36%
#5 QuantixAI QuantixAI +23.76%
#6 EXOD EXOD +22.78%
#7 Derive Derive +19.90%
#8 Cash Cat Cash Cat +16.73%
#9 Pons Pons +16.53%
#10 BNB Attestation Service BNB Attestation Service +16.09%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Cypherpunk Technologies Inc. Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc.

CYPH
Rang in Aktien #19166
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the... Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Aktienkurs
$1.62
Zuletzt synchronisiert: 2026-08-25
Marktkapitalisierung
$172.47M
Veränderung (1 Tag)
-3.57%
Veränderung (1 Jahr)
446.74%
Land
US
Handel Cypherpunk Technologies Inc. (CYPH)

Kategorie

Healthcare
P/B-Verhältnis für Cypherpunk Technologies Inc. (CYPH)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Cypherpunk Technologies Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Cypherpunk Technologies Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH